Inhibitors targeting BamA in gram-negative bacteria
- PMID: 37852326
- DOI: 10.1016/j.bbamcr.2023.119609
Inhibitors targeting BamA in gram-negative bacteria
Abstract
Antibiotic resistance has led to an increase in the number of patient hospitalizations and deaths. The situation for gram-negative bacteria is especially dire as the last new class of antibiotics active against these bacteria was introduced to the clinic over 60 years ago, thus there is an immediate unmet need for new antibiotic classes able to overcome resistance. The outer membrane, a unique and essential structure in gram-negative bacteria, contains multiple potential antibacterial targets including BamA, an outer membrane protein that folds and inserts transmembrane β-barrel proteins. BamA is essential and conserved, and its outer membrane location eliminates a barrier that molecules must overcome to access this target. Recently, antibacterial small molecules, natural products, peptides, and antibodies that inhibit BamA activity have been reported, validating the druggability of this target and generating potential leads for antibiotic development. This review will describe these BamA inhibitors, highlight their key attributes, and identify challenges with this potential target.
Keywords: Antibiotics; BamA; Gram-negative bacteria; Outer membrane proteins; β-Barrel protein folding.
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Steven T. Rutherford reports financial support was provided by Genentech Inc. Kelly M. Storek reports financial support was provided by Genentech Inc. Dawei Sun reports financial support was provided by Genentech Inc. Steven T. Rutherford reports a relationship with Genentech Inc. that includes: employment. Kelly M. Storek reports a relationship with Genentech Inc. that includes: employment. Dawei Sun reports a relationship with Genentech Inc. that includes: employment. All authors on this manuscript are employees of Genentech, Inc., a member of the Roche Group, and shareholders in Roche. Genentech, Inc. had no role in the preparation or content of this work or the decision to submit it for publication.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources